← Human Trials & Peer-Reviewed Studies
Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans
Plain-language guide to PMID 18843793 (2008): randomized controlled trial study of IGF-1 LR3 in 3 volunteers.
Key Facts
- PMID
- 18843793
- Journal
- Aging cell
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Fontana L et al. (5 authors)
- DOI
- 10.1111/j.1474-9726.2008.00417.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of IGF-1 LR3, published as a randomized controlled trial.
However, the long-term effects of CR with adequate nutrition on circulating IGF-1 levels in humans are unknown.
Here the researchers report data from two long-term CR studies (1 and 6 years) showing that severe CR without malnutrition did not change IGF-1 and IGF-1 : IGFBP-3 ratio levels in humans.
Who Took Part
The study group was 3 volunteers.
The age groups tagged for this paper are middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.
A time span of 3 weeks appears in the methods.
What Was Measured
However, the long-term effects of CR with adequate nutrition on circulating IGF-1 levels in humans are unknown.
Here the researchers report data from two long-term CR studies (1 and 6 years) showing that severe CR without malnutrition did not change IGF-1 and IGF-1 : IGFBP-3 ratio levels in humans.
Topics PubMed links to this paper include Aging, Caloric Restriction, Dietary Proteins, Energy Intake, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor Binding Proteins and Insulin-Like Growth Factor I.
What This Means in Plain Language
The paper is a randomized study of IGF-1 LR3 in 3 volunteers over 3 weeks.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2008 (Aging cell), a journal based in England.
More context: the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.